​

Tempest Therapeutics (TPST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TPST Stock Rating

Tempest Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

TPST Price Target Upside V Benchmarks

TypeNameUpside
StockTempest Therapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$7.11$7.11$7.11
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--2--2
May, 25112--4
Apr, 2532---5
Mar, 2532---5
Feb, 2532---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 28, 2025H.C. WainwrightBuyBuyhold
Nov 13, 2024Piper SandlerOverweightOverweighthold
Oct 14, 2024ScotiabankSector OutperformSector Outperformhold
Oct 11, 2024H.C. WainwrightBuyBuyhold
Aug 16, 2024ScotiabankSector OutperformSector Outperformhold
May 13, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.80$-1.91$-1.50----
Avg Forecast$-6.41$-1.93$-1.35$-1.04$-1.28$-1.28$-0.98
High Forecast$-6.41$-1.82$-1.23$-0.79$-0.68$-0.52$-0.98
Low Forecast$-6.41$-1.99$-1.42$-1.44$-2.12$-2.26$-0.98
Surprise %21.68%-1.04%11.11%----

Revenue Forecast

$15M $24M $33M $42M $51M $60M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$137.79K---$17.85M$57.82M$25.30M
High Forecast$165.35K---$17.85M$57.82M$25.30M
Low Forecast$110.23K---$17.85M$57.82M$25.30M
Surprise %-------

Net Income Forecast

$-90M $-73M $-56M $-39M $-22M $-5M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-29.55M$-29.49M$-41.84M----
Avg Forecast$-73.09M$-29.49M$-20.45M$-17.17M$-21.61M$-21.43M$-15.03M
High Forecast$-58.47M$-28.13M$-18.96M$-12.21M$-10.50M$-8.02M$-15.03M
Low Forecast$-87.71M$-30.74M$-21.94M$-22.13M$-32.72M$-34.84M$-15.03M
Surprise %-59.57%-104.63%----

TPST Forecast FAQ

Is Tempest Therapeutics stock a buy?

Tempest Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tempest Therapeutics is a favorable investment for most analysts.

What is Tempest Therapeutics's price target?

Tempest Therapeutics's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $7.11.

How does Tempest Therapeutics stock forecast compare to its benchmarks?

Tempest Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Tempest Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Tempest Therapeutics’s EPS forecast?

Tempest Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.04, marking a -30.67% decrease from the reported $-1.5 in 2024. Estimates for the following years are $-1.28 in 2026, $-1.28 in 2027, and $-0.98 in 2028.

What is Tempest Therapeutics’s revenue forecast?

Tempest Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $17.85M, followed by $57.82M for 2027, and $25.3M for 2028.

What is Tempest Therapeutics’s net income forecast?

Tempest Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-17.173M, representing a -58.96% decrease from the reported $-41.843M in 2024. Projections indicate $-21.611M in 2026, $-21.429M in 2027, and $-15.031M in 2028.